# Revolution Medicines

Source: https://onco.cc/companies/revolution-medicines/  
OnCo record `revolution-medicines` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Revolution Medicines is the leading RAS company, with daraxonrasib in phase 3 for pancreatic cancer.

## Summary

Revolution Medicines, based in Redwood City, California, and listed as RVMD, is the leading RAS company, with daraxonrasib in phase 3 for pancreatic cancer. Its pipeline pairs daraxonrasib, a pan-RAS inhibitor, with elironrasib, selective for G12C in the active state, and zoldonrasib against G12D, tested in the RASolute and RASolve phase 3 programmes, and the company expanded its credit facility in 2025 to fund a launch. OnCo links it to pancreatic ductal adenocarcinoma, to the KRAS roadmap from undruggable through G12C to pan-RAS, to the bottleneck of undruggable drivers, and to the idea of covalent chemistry for RAS mutations that still have no drug. Whether pan-RAS inhibition is tolerable enough for long-term use is the open question. Daraxonrasib has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- Also known as: EQRx International, Inc.; EQRx
- HQ: Redwood City, CA
- Type: biotech
- Website: https://www.revmed.com
- Ticker: RVMD

## Sources

- Official website: https://www.revmed.com

## Connected records

- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [Daraxonrasib](https://onco.cc/drugs/daraxonrasib/), [Elironrasib](https://onco.cc/drugs/elironrasib/), [Zoldonrasib](https://onco.cc/drugs/zoldonrasib/)
- trials: [RASolute 302](https://onco.cc/trials/rasolute-302/), [Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)](https://onco.cc/trials/nct06881784/), [Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)](https://onco.cc/trials/nct07252232/), [Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma](https://onco.cc/trials/nct07491445/), [Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors](https://onco.cc/trials/nct06128551/), [Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mu](https://onco.cc/trials/nct07777822/), [Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors](https://onco.cc/trials/nct07397338/), [Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC](https://onco.cc/trials/nct06162221/), [Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors](https://onco.cc/trials/nct06445062/), [Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS](https://onco.cc/trials/nct05379985/), [Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors](https://onco.cc/trials/nct06040541/), [Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mut](https://onco.cc/trials/nct07805954/), [Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-muta](https://onco.cc/trials/nct07621718/)
- cancers: [Borderline resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/borderline-resectable-pdac/), [KRAS G12C-mutant pancreatic ductal adenocarcinoma](https://onco.cc/cancers/kras-g12c-pdac/), [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- key papers: [Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy](https://onco.cc/key-papers/paper-holderfield-ras-on-multi-selective-inhibitor-nature-2024/)
- roadmaps: [KRAS roadmap: undruggable → G12C → pan-RAS](https://onco.cc/roadmaps/kras-roadmap/), [Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question](https://onco.cc/roadmaps/pancreatic-roadmap/)
- ideas: [Covalent chemistry for the RAS mutations that still have no drug](https://onco.cc/ideas/idea-bio1-pan-ras-covalent-g12d/), [RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression](https://onco.cc/ideas/idea-pdac-ras-inhibitor-combinations-and-sequencing/)
- technologies: [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/)
- bottlenecks: [The undruggable drivers](https://onco.cc/bottlenecks/b-undruggable-targets/)
- companies: [Bain Capital Life Sciences](https://onco.cc/companies/bain-capital-life-sciences/), [Boxer Capital](https://onco.cc/companies/boxer-capital/)

---
JSON: https://onco.cc/api/v1/entities/revolution-medicines.json